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Conclusion
GH-treated SRS patients have similar metabolic health as non-SRS subjects born SGA, and show no adverse events during and two years after long-term GH-treatment
Background
Children with Silver-Russell syndrome (SRS) are born small for gestational age (SGA) and remain short.
Growth hormone (GH)-treatment improves height in short SGA children, including SRS patients¹.
Data on metabolic health and long-term safety of GH-treatment in SRS are lacking.
Results
Objectives
To investigate metabolic health in SRS patients, during and after longterm GH-treatment.
Methods
In 29 SRS* and 246 non-SRS subjects born SGA, we measured -Systolic blood pressure (SBP) and diastolic blood pressure (DBP) -Serum lipid levels -Fat Mass percentage (FM%) and Lean Body Mass (LBM) by DEXA-scan -Insulin sensitivity and ß-cell function by FSIGT -Risk for metabolic syndrome (ATP-III score)
Both groups received GH-treatment 1 mg/m2/day. Parameters were compared at GH-start, at adult height/GH-stop, and six months and two years thereafter.
*Diagnosis based on the Netchine-Harbison clinical scoring system². In all SRS patients, additional DNA testing for 11p15 alterations, mUPD7 and CDKN1C and IGF2 mutations was performed Except for a lower SBP SDS at GH-start (p=0.02), and a lower LBM SDS at GH-stop and 6 months thereafter (p=0.005 and p=0.01) in SRS, there were neither differences in risk for cardiovascular disease and DM2 between SRS and non-SRS at onset of GH treatment, nor at GH-stop and six months and two years thereafter (Figure 1 ).
Lipid levels were similar and within the normal range in both groups at all moments. None of the SRS patients developed metabolic syndrome or DM2 until two years after GH-stop (mean age 18.3 years).
SRS patients benefit similarly with respect to the metabolic effects of GH treatment as non-SRS SGA. Figure 1: Blood pressure and body composition in SRS and non-SRS at GH-start, GH-stop and 6 months and 2 years therafter. In Estimated Means (±SE). * = p<0.05
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